Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
Sanwa Kagaku Kenkyusho said on October 23 that its secondary hyperparathyroidism (SHPT) treatment SK-1403 (upacicalcet) hit its primary endpoint in a Japan PIII clinical study in SHPT patients on dialysis. The data were presented at the American Society of Nephrology…
To read the full story
Related Article
- Sanwa Kagaku Files SHPT Med for Japan Approval
August 26, 2020
BUSINESS
- Nipro Eyes 50-60 Stemirac Treatment Sites across Japan after Full Nod
November 20, 2026
- AstraZeneca’s Etcamah to Hit Japan Market on Nov. 27
November 20, 2026
- Japan Drug Makers’ Sales Seen Dipping in FY2026 on Co-Marketing Exits
November 20, 2026
- J&J’s Icotyde Could Broaden Psoriasis Treatment Options: Expert
November 20, 2026
- Nippon Kayaku to Acquire AstraZeneca’s Zoladex on Dec. 16
November 20, 2026





